Atenolol and Timolol

New England Journal of Medicine

Volumn 307, Issue 21, 1982, Pages 1343-1346

  Rössner, Stephan ^a   Weiner, Leif ^b   Westerlund, Anders ^c   Zonszein, Joel ^d   Baylor, Peter ^d   Lawrence, D S ^e   Sahay, J N ^e   Chatterjee, S S ^f   Griffing, George T ^g   Coakley, Christopher E ^g   Lessell, Simmons ^g   Melby, James C ^g   Vozeh S ^h   Frishman, William H ⁱ  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Karlskoga Hospital   (Sweden)

^c Västra Frölunda Hospital ^*  (Sweden)

^d BRONX LEBANON HOSPITAL CENTER   (United States)

^e CLATTERBRIDGE HOSPITAL   (United Kingdom)

^f WYTHENSHAWE HOSPITAL   (United Kingdom)

^g University Hospital   (United States)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; HIGH DENSITY LIPOPROTEIN; TIMOLOL; VERY LOW DENSITY LIPOPROTEIN;

ADVERSE DRUG REACTION; CARDIOVASCULAR SYSTEM; EDITORIAL; HYPERLIPOPROTEINEMIA; HYPERTENSION;

ADULT; AGED; ATENOLOL; CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; TIMOLOL;

EID: 0019939852     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198211183072116     Document Type: Letter

References (28)

1. Frishman W.H. Atenolol and timolol, two new systemic β-adrenoceptor antagonists. N Engl J Med. 1982; 306:1456-1462
2. Rössner S. Serum lipoproteins and ischemic vascular disease: on the interpretation of serum lipid versus serum lipoprotein concentrations. J Cardiovasc Pharmacol. 1982; 4:S201-5.
3. Thomas G.W., Mann J.I., Beilin L.J., Ledingham J.G. Hypertension and raised serum lipids. Br Med J. 1977; 2:805.
4. Eliasson K., Lins L.E., Rössner S. Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol. 1981; 20:335-338
5. Ingbar S.H., Woeber K.A. The thyroid gland. In: Williams R, ed. Textbook of endocrinology. 6th ed. Philadelphia: WB Saunders, 1981: 192-200.
6. Zonszein J., Santangelo R.P., Mackin J.F., Lee T.C., Coffey R.J., Canary J.J. Propranolol therapy in thyrotoxicosis: a review of 84 patients undergoing surgery. Am J Med. 1979; 66:411-416
7. Frishman W.H. Beta-adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-506
8. How J., Khir A.S.M., Bewsher P.D. The effect of atenolol on serum thyroid hormones in hyperthyroid patients. Clin Endocrinol (Oxf). 1980; 13:299-302.
9. Nilsson O.R., Karlberg B.E., Kagedal B., Tegler L., Almqvist S. Non-selective and selective beta-1-adrenoceptor blocking agents in the treatment of hyperthyroidism. Acta Med Scand. 1979; 206:21-25
10. McDevitt D.G., Nelson J.K. Comparative trial of atenolol and propranolol in hyperthyroidism. Br J Clin Pharmacol. 1978; 6:233-237
11. Nelson J.K., McDevitt D.G. Beta-blockade in thyrotoxicosis: is the cardioselective drug atenolol as satisfactory as propranolol? Ir J Med Sci. 1979: 148:156. abstract.
12. Feely J., Stevenson I.H., Crooks J. Increased clearance of propranolol in thyrotoxicosis. Ann Intern Med. 1981; 94:472-474
13. Tattersfield A.E., Mackay A.D., Gribbin H.R., Baldwin C.J. How cardioselective are the new beta-blocking drugs? Presented at the 6th Scientific Meeting of the International Society of Hypertension, Gothenburg, June 1979. abstract.
14. Harrison R.N., Tattersfield A.E. The cardioselectivity of atenolol and metoprolol at 2 and 24 hours after a single dose. Presented at the 9th Scientific Meeting of the International Society of Hypertension, Mexico, February 1982. abstract.
15. Harry J.D., Cruickshank J.M., Young J., Barker N. Relative activities of atenolol and metoprolol on the cardiovascular system of man. Eur J Clin Pharmacol. 1981; 20:9-15.
16. Ballin N., Becker B., Goldman M.L. Systemic effects of epinephrine applied topically to the eye. Invest Ophthal. 1966; 5:125-129
17. Adverse systemic effects from ophthalmic drugs. Med Lett Drugs Ther. 1982; 24:53-54
18. Heel R.C., Brogden R.N., Speight T.M., Avery G.S. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs. 1979; 17:38-55.
19. Podos S.M., Ritch R. Epinephrine as the initial therapy in selected cases of ocular hypertension. Surv Ophthalmol. 1980: 22:188-194
20. Van Buskirk E.M. Adverse reactions from timolol administration. Ophthalmology (Rochester). 1980; 87:447-450
21. Bravo E.L., Tarazi R.C., Fouad F.M., Vidt D.G., Gifford R.W. Jr. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med. 1981; 305:623-626
22. Briggs R.S.J., Birtwell A.J., Pohl J.E.F. Hypertensive response to labetalol in phaeochromocytoma. Lancet. 1978; 1:1045-1046
23. Cass E., Kadar D., Stein H.A. Hazards of phenylephrine topical medication in persons taking propranolol. Can Med Assoc J. 1979; 120:1261-1262
24. Phenylephrine, eye drops and β-blockers. Med Lett Drugs Ther. 1982; 24:70.
25. Rowland M., Tozer T.N. Clinical pharmacokinetics. Philadelphia: Lea & Febiger, 1980: 93.
26. Johnson B. The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol. 1982; 4: Suppl 2:5213-5221
27. Day J.L., Simpson N., Metcalfe J., et al. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J. 1979; 1:77-80.
28. Frishman W., Michelson E., Johnson B., et al. Effects of beta-adrenergic blockade on plasma lipids: a double-blind randomized placebo-controlled multi-center comparison of labetalol and metaprolol in patients with hypertension. Am J Cardiol. 1982; 49:984. abstract.